KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Gross Profit (2016 - 2025)

Emergent BioSolutions' Gross Profit history spans 15 years, with the latest figure at $63.8 million for Q4 2025.

  • For Q4 2025, Gross Profit fell 16.82% year-over-year to $63.8 million; the TTM value through Dec 2025 reached $416.7 million, up 3.22%, while the annual FY2025 figure was $416.7 million, 15.02% up from the prior year.
  • Gross Profit reached $63.8 million in Q4 2025 per EBS's latest filing, down from $145.2 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $731.1 million in Q4 2021 to a low of $11.4 million in Q1 2023.
  • Average Gross Profit over 5 years is $174.7 million, with a median of $147.3 million recorded in 2023.
  • Peak YoY movement for Gross Profit: crashed 94.94% in 2023, then surged 1266.67% in 2024.
  • A 5-year view of Gross Profit shows it stood at $731.1 million in 2021, then tumbled by 77.72% to $162.9 million in 2022, then plummeted by 43.83% to $91.5 million in 2023, then fell by 16.17% to $76.7 million in 2024, then dropped by 16.82% to $63.8 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Gross Profit are $63.8 million (Q4 2025), $145.2 million (Q3 2025), and $74.0 million (Q2 2025).